Every drug developer keeps a private list of what could sink a program: the efficacy readout, a safety scare, a regulator with second thoughts. The generic in the comparator arm almost never makes the list. It is the bridge you drive across every morning without a thought, until the morning it is closed and there is no other way over.
It's Friday, so we slow down and look at the bridge. Drug shortages normally read as a clinic story: one patient, one substitution, one hard conversation at the chair. This one runs upstream, into the trials meant to produce the next cancer drugs, and the striking part is not that it happened at all but that it keeps happening.
Take a late-phase oncology trial. Its comparator arm is built on carboplatin or cisplatin, because a new therapy has to prove itself against the standard of care, and for a lot of cancers, that standard is a platinum generic. The design was locked, reviewed by an ethics committee and a regulator, then set running. As of July 16, carboplatin was still on the US shortage list. So the fixed, pre-specified thing at the center of that study, the drug the new therapy is measured against, is now something the sponsor cannot assume will be in the cabinet next month.
That is the shift this story is really about. "Clinical trials rely on strict protocol adherence to evaluate a new treatment's efficacy against standard-of-care agents. Shortages force investigators to substitute alternative drugs, reduce doses, or omit critical agents entirely, which disrupts the trial's standardized data and threatens the validity of the research," Dr. Julie R Gralow, chief medical officer of the American Society of Clinical Oncology (ASCO), told In Vivo. She put the stakes more plainly: "because many oncology trials evaluate a new drug in combination with or compared to a standard generic drug, a shortage of the generic baseline drug halts the entire study, potentially delaying approval and commercial rollout of potentially life-saving new cancer therapies."
The drug nobody budgets for, sitting in the comparator arm on thin generic margins, turns out to be load-bearing.
The Numbers, And Why A Smaller One Isn't Good News
Active US drug shortages reached 227 in the second quarter of 2026, up for the third quarter in a row, according to the American Society of Health-System Pharmacists, with chemotherapy among the problem areas. That is below the all-time high of 323 in the first quarter of 2024, and the temptation is to read the lower figure as a recovery. ASHP's own caution cuts against that: a single shortage can touch enormous numbers of patients, so a shorter list does not mean a smaller problem. The other number matters more anyway. The average shortage reached over five years in 2025, up from 4.3 years in 2024 and roughly two in 2019, per the US Pharmacopeia's annual report. A shortage is no longer an event you wait out. It is a condition you plan around.